Literature DB >> 15343582

'Lipoproteins, glycoxidation and diabetic angiopathy'.

Alicia J Jenkins1, James D Best, Richard L Klein, Timothy J Lyons.   

Abstract

The chronic vascular complications of diabetes (nephropathy, retinopathy and accelerated atherosclerosis) are a major cause of morbidity and premature mortality. In spite of the more widespread availability of intensive diabetes management, approximately one in three people with diabetes develop aggressive complications and over 70% die of atherosclerosis-related diseases. Genetic and acquired factors are likely to be contributory. Potential mediators of vascular damage may include the interrelated processes of lipoprotein abnormalities, glycation, oxidation and endothelial dysfunction. Lipoprotein abnormalities encompass alterations in lipid concentrations, lipoprotein composition and subclass distribution and lipoprotein-related enzymes. Nonenzymatic glycation and oxidative damage to lipoproteins, other proteins and to vascular structures may also be deleterious. As atherosclerosis is a chronic condition commencing in youth, and because clinical events may be silent in diabetes, surrogate measures of vascular disease are important for early identification of diabetic patients with or at high risk of vascular damage, and for monitoring efficacy of interventions. The increasing array of biochemical assays for markers and mediators of vascular damage, noninvasive measures of vascular health, and therapeutic options should enable a reduction in the excessive personal and economic burden of vascular disease in type 1 and type 2 diabetes. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15343582     DOI: 10.1002/dmrr.491

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  24 in total

1.  Tyrosine nitration of prostacyclin synthase is associated with enhanced retinal cell apoptosis in diabetes.

Authors:  Ming-Hui Zou; Hongliang Li; Chaoyong He; Mingkai Lin; Timothy J Lyons; Zhonglin Xie
Journal:  Am J Pathol       Date:  2011-10-18       Impact factor: 4.307

Review 2.  The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it.

Authors:  Alicia Jenkins; Andrzej Januszewski; David O'Neal
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-02-13

Review 3.  New frontiers in the treatment of diabetic dyslipidemia.

Authors:  Shu-Yi Wang; Ming-Chia Hsieh; Shih-Te Tu; Chieh-Sen Chuang
Journal:  Rev Diabet Stud       Date:  2013-08-10

4.  Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort.

Authors:  Alicia J Jenkins; Jeremy Yu; Petar Alaupovic; Arpita Basu; Richard L Klein; Maria Lopes-Virella; Nathaniel L Baker; Kelly J Hunt; Daniel T Lackland; W Timothy Garvey; Timothy J Lyons
Journal:  J Diabetes Complications       Date:  2013-07-11       Impact factor: 2.852

Review 5.  Overlapped metabolic and therapeutic links between Alzheimer and diabetes.

Authors:  Waqar Ahmad
Journal:  Mol Neurobiol       Date:  2012-09-26       Impact factor: 5.590

6.  LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses.

Authors:  Richard L Klein; Rickey E Carter; Alicia J Jenkins; Timothy J Lyons; Nathaniel L Baker; Gregory E Gilbert; Gabriel Virella; Maria F Lopes-Virella
Journal:  J Diabetes Complications       Date:  2010-06-03       Impact factor: 2.852

Review 7.  Treatment approaches for diabetes and dyslipidemia.

Authors:  Mingyuan Wu; Timothy J Lyons
Journal:  Horm Res Paediatr       Date:  2011-07-21       Impact factor: 2.852

8.  Increased serum kallistatin levels in type 1 diabetes patients with vascular complications.

Authors:  Alicia J Jenkins; Jeffrey D McBride; Andrzej S Januszewski; Connie S Karschimkus; Bin Zhang; David N O'Neal; Craig L Nelson; Jasmine S Chung; C Alex Harper; Timothy J Lyons; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-09-22

9.  Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins.

Authors:  B E Brown; F M Mahroof; N L Cook; D M van Reyk; M J Davies
Journal:  Diabetologia       Date:  2006-02-08       Impact factor: 10.122

Review 10.  Biomarkers in Diabetic Retinopathy.

Authors:  Alicia J Jenkins; Mugdha V Joglekar; Anandwardhan A Hardikar; Anthony C Keech; David N O'Neal; Andrzej S Januszewski
Journal:  Rev Diabet Stud       Date:  2015-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.